Beta-thalassemia (B-thal) Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies – Phoenicia, EdiGene, Imara, Agios, Ionis
To counter unmet market needs and provide better treatment choices for beta-thalassemia, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the near future, likely to drive market growth during the study period. Bluebird Bio, Agios Pharmaceutical, Ionis Pharmaceutical, and others are the leading pharma and biotech players in the beta thalassemia market. Some of the key products in the Beta-thalassemia therapeutics market landscape include Zynteglo (LentiGlobin BB305), Mitapivat, Sapablursen, among others.
DelveInsight’s “Beta-thalassemia (B-thal) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Beta-thalassemia (B-thal) market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Beta-thalassemia (B-thal) market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Beta-thalassemia (B-thal): An Overview
Beta thalassemia (β-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.
The symptoms of severe untreated β-thalassemia include severe anemia, with a Hb level of 3−7 g/dL, massive hepatosplenomegaly, severe growth retardation, and Bone deformities. People with beta-thalassemia major or intermediate usually have a buildup of iron in the body, either from the disease itself or from repeated blood transfusions. Excess iron can damage the heart, liver, and endocrine system. People with the minor form of Beta Thalassemia have small red blood cells but no symptoms.
Beta thalassemia includes three primary forms: thalassemia major (variably referred to as “Cooley’s Anemia” and “Mediterranean Anemia), thalassemia intermediate, and thalassemia minor (also called “beta thalassemia carrier,” “beta thalassemia trait” or “heterozygous beta thalassemia”).
Beta-thalassemia (B-thal) Market Key Facts
The market size of beta-thalassemia in the United States and the EU5 (Germany, Spain, Italy, France, and the United Kingdom) was found to be USD 364.3 in 2020.
In 2020, the total prevalent cases of beta thalassemia were the highest in Italy, with 7,100+ cases, and the lowest in Spain, with 276 cases.
Spain had the lowest prevalent population of beta-thalassemia (270+ cases) in 2020.
According to National Hemoglobinopathy Registry (NHR) annual report 2020, there were >900 beta-thalassemia major patients and >200 beta-thalassemia intermedia patients living in the UK.
According to DelveInsight’s estimates, the US accounted for 1,000+ cases each of beta-thalassemia intermediate and beta-thalassemia major in 2020.
The disease is not well studied globally; however, few estimates exist, which suggest that the total annual incidence of symptomatic individuals is estimated at 1 in 100,000 throughout the world and 1 in 10,000 people in the European Union (Lolascon et al., 2019). However, these estimates do not correspond to the actual patients diagnosed with beta-thalassemia condition in the form of a disease and not in the form of a trait or a carrier.
Beta-thalassemia (B-thal) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Beta-thalassemia (B-thal) market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Beta-thalassemia (B-thal) market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Beta-thalassemia (B-thal) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Beta-thalassemia (B-thal) Epidemiology, Segmented as –
Total Prevalent Population of Beta Thalassemia (2019–2032)
Total Prevalent Cases of Beta Thalassemia Minor (2019–2032)
Diagnosed Prevalence of Beta Thalassemia (2019–2032)
Diagnosed Beta-Thalassemia Patients by Disease Type (2019–2032)
Beta-thalassemia (B-thal) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Beta-thalassemia (B-thal) market or expected to be launched during the study period. The analysis covers the Beta-thalassemia (B-thal) market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Beta-thalassemia (B-thal) pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Beta-thalassemia (B-thal) Market Will Evolve and Grow by 2032 @
Beta-thalassemia (B-thal) Therapeutics Market
Several major pharma and biotech giants are actively developing therapies for Beta thalassemia (B-thal). Currently, Imara is leading the therapeutics market with its Beta thalassemia (B-thal) drug candidates in the most advanced stage of clinical development.
Leading Companies in the Beta Thalassemia Therapeutics Market Include:
Acceleron Pharma, Agios Pharmaceuticals, Inc., Allife Medical Science and Technology, Aruvant Sciences, Beam Therapeutics, Bioray Laboratories, Bluebird Bio, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, CRISPR Therapeutics, Disc Medicine, DisperSol Technologies, EdiGene (GuangZhou) Inc., Editas Medicine, EmeraMed, Forma Therapeutics, Fulcrum Therapeutics, Global Blood Therapeutics, Inc, Graphite Bio, Imara, Inc., Ionis Pharmaceuticals, Inc., Merck, Novartis, Orchard Therapeutics, Phoenicia Biosciences, Regenacy Pharmaceuticals, San Rocco Therapeutics, Sangamo Therapeutics, Shanghai BDgene, Silence Therapeutics plc, Vertex Pharmaceuticals, Vifor Pharma, and many others.
Beta Thalassemia Emerging and Marketed Drugs Covered in the Report Include:
Benserazide: Phoenicia Biosciences
CTX001: CRISPR Therapeutics
EDIT-301: Editas Medicine
ET-01: EdiGene Inc
GPH 102: Graphite Bio
Mitapivat: Agios Pharmaceutical
Sapablursen: Ionis Pharmaceutical
SLN124: Silence Therapeutics
Vamifeport: Vifor Pharma
Zynteglo (LentiGlobin BB305): Bluebird Bio
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Beta-thalassemia (B-thal) Competitive Intelligence Analysis
4. Beta-thalassemia (B-thal) Market Overview at a Glance
5. Beta-thalassemia (B-thal) Disease Background and Overview
6. Beta-thalassemia (B-thal) Patient Journey
7. Beta-thalassemia (B-thal) Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Beta-thalassemia (B-thal) Treatment Algorithm, Current Treatment, and Medical Practices
9. Beta-thalassemia (B-thal) Unmet Needs
10. Key Endpoints of Beta-thalassemia (B-thal) Treatment
11. Beta-thalassemia (B-thal) Marketed Products
12. Beta-thalassemia (B-thal) Emerging Drugs and Latest Therapeutic Advances
13. Beta-thalassemia (B-thal) Seven Major Market Analysis
14. Attribute Analysis
15. Beta-thalassemia (B-thal) Market Outlook (In US, EU5, and Japan)
16. Beta-thalassemia (B-thal) Access and Reimbursement Overview
17. KOL Views on the Beta-thalassemia (B-thal) Market
18. Beta-thalassemia (B-thal) Market Drivers
19. Beta-thalassemia (B-thal) Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States